Triptolide induces growth inhibition and apoptosis of human laryngocarcinoma cells by enhancing p53 activities and suppressing E6-mediated p53 degradation

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Zhao, Fei ^a   Huang, Weiwei ^a   Ousman, Tamgue ^a   Zhang, Bin ^a   Han, Yangyang ^a   Clotaire, Daguia Zambe John ^a   Wang, Chen ^a   Chang, Huanhuan ^b   Luo, Huanan ^b   Ren, Xiaoyong ^b   Lei, Ming ^a  

^a NORTHWEST A F UNIVERSITY   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DITERPENE; EPOXIDE; ONCOPROTEIN; PHENANTHRENE DERIVATIVE; PROTEIN P53; TRIPTOLIDE;

APOPTOSIS; DRUG EFFECTS; HUMAN; LARYNX TUMOR; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DITERPENES; EPOXY COMPOUNDS; HUMANS; LARYNGEAL NEOPLASMS; ONCOGENE PROTEINS, VIRAL; PHENANTHRENES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84893529503     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080784     Document Type: Article

References (61)

1. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N et al. (2013) SEER Cancer Statistics Review, 1975-2010. National Cancer Institute: Bethesda, MD. Available: http://seer.cancer.gov/csr/1975-2010/. Based on November 2012 SEER data submission, posted to the SEER web site
2. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1): 11-30. doi:10.3322/caac.21166. PubMed: 23335087.
3. Vu HL, Sikora AG, Fu S, Kao J (2010) HPV-induced oropharyngeal cancer, immune response and response to therapy. Cancer Lett 288(2): 149-155. doi:10.1016/j.canlet.2009.06.026. PubMed: 19628331.
4. Crook T, Tidy JA, Vousden KH (1991) Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell. 67(3): 547-556. doi:10.1016/0092-8674(91)90529-8. PubMed: 1657399.
5. Bernard X, Robinson P, Nominé Y, Masson M, Charbonnier S et al. (2011) Proteasomal degradation of p53 by human papillomavirus E6 oncoprotein relies on the structural integrity of p53 core domain. PLOS ONE. 6(10): e25981. doi:10.1371/journal.pone.0025981. PubMed: 22046250.
6. Boyer SN, Wazer DE, Band V (1996) E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 56(20): 4620-4624. PubMed: 8840974.
7. Levine AJ, Oren M (2009) The first 30 years of p53: growing ever more complex. Nat Rev Cancer. 9(10): 749-758. doi:10.1038/nrc2723. PubMed: 19776744.
8. Meek DW (2009) Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer. 9(10): 714-723. PubMed: 19730431.
9. Junttila MR, Evan GI (2009) p53 - a Jack of all trades but master of none. Nat Rev Cancer. 9(11): 821-829. doi:10.1038/nrc2728. PubMed: 19776747.
10. Brosh R, Rotter V (2009) When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer. 9(10): 701-713. PubMed: 19693097.
11. Wang Z, Sun Y (2010) Targeting p53 for Novel Anticancer Therapy. Transl Oncol 3(1): 1-12. PubMed: 20165689.
12. Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG et al. (2004) Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 10(12): 1321-1328. doi:10.1038/nm1146. PubMed: 15558054.
13. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F et al. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 303(5659): 844-848. doi:10.1126/science.1092472. PubMed: 14704432.
14. Liu Q (2011) Triptolide and its expanding multiple pharmacological functions. Int Immunopharmacol 11(3): 377-383. doi:10.1016/j.intimp.2011.01.012. PubMed: 21255694.
15. Lee KY, Park JS, Jee YK, Rosen GD (2002) Triptolide sensitizes lung cancer cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by inhibition of NF-kappaB activation. Exp Mol Med 34(6): 462-468. doi:10.1038/emm.2002.64. PubMed: 12526088.
16. Mujumdar N, Mackenzie TN, Dudeja V, Chugh R, Antonoff MB et al. (2010) Triptolide induces cell death in pancreatic cancer cells by apoptotic and autophagic pathways. Gastroenterology. 139(2): 598-608. doi:10.1053/j.gastro. 2010.04.046. PubMed: 20434451.
17. Tan BJ, Tan BH, Chiu GN (2011) Effect of triptolide on focal adhesion kinase and survival in MCF-7 breast cancer cells. Oncol Rep 26(5): 1315-1321. PubMed: 21805042.
18. Zhao H, Yang Z, Wang X, Zhang X, Wang M et al. (2012) Triptolide inhibits ovarian cancer cell invasion by repression of matrix metalloproteinase 7 and 19 and upregulation of E-cadherin. Exp Mol Med 44(11): 633-641. doi:10.3858/emm.2012.44.11.072. PubMed:
19. Li J, Zhu W, Leng T, Shu M, Huang Y et al. (2011) Triptolide-induced cell cycle arrest and apoptosis in human renal cell carcinoma cells. Oncol Rep 25(4): 979-987. PubMed: 21271220.
20. Lin J, Chen LY, Lin ZX, Zhao ML (2007) The effect of triptolide on apoptosis of glioblastoma multiforme (GBM) cells. J Int Med Res 35(5): 637-643. doi:10.1177/147323000703500508. PubMed: 17900403.
21. Zhu W, Hu H, Qiu P, Yan G (2009) Triptolide induces apoptosis in human anaplastic thyroid carcinoma cells by a p53-independent but NF-kappaB-related mechanism. Oncol Rep 22(6): 1397-1401. PubMed: 19885592.
22. Carter BZ, Mak DH, Shi Y, Fidler JM, Chen R et al. (2012) MRx102, a triptolide derivative, has potent antileukemic activity in vitro and in a murine model of AML. Leukemia. 26(3): 443-450. doi:10.1038/leu.2011.246. PubMed: 21904380.
23. Johnson SM, Wang X, Evers BM (2011) Triptolide inhibits proliferation and migration of colon cancer cells by inhibition of cell cycle regulators and cytokine receptors. J Surg Res 168(2): 197-205. doi:10.1016/j.jss.2009.07.002. PubMed: 19922946.
24. Huang W, He T, Chai C, Yang Y, Zheng Y et al. (2012) Triptolide inhibits the proliferation of prostate cancer cells and down-regulates SUMO-specific protease 1 expression. PLOS ONE.7(5): e37693. doi:10.1371/journal.pone.0037693. PubMed: 22666381.
25. Chang WT, Kang JJ, Lee KY, Wei K, Anderson E et al. (2001) Triptolide and chemotherapy cooperate in tumor cell apoptosis. A role for the p53 pathway. J Biol Chem 276(3): 2221-2227. PubMed: 11053449.
26. Zhu W, He S, Li Y, Qiu P, Shu M et al. (2010) Anti-angiogenic activity of triptolide in anaplastic thyroid carcinoma is mediated by targeting vascular endothelial and tumor cells. Vascul Pharmacol 52(1-2): 46-54. doi:10.1016/j.vph.2009.10.006. PubMed: 19854299.
27. Yang S, Chen J, Guo Z, Xu XM, Wang L et al. (2003) Triptolide inhibits the growth and metastasis of solid tumors. Mol Cancer Ther 2(1): 65-72. PubMed: 12533674.
28. Titov DV, Gilman B, He QL, Bhat S, Low WK et al. (2011) XPB, a subunit of TFIIH, is a target of the natural product triptolide. Nat Chem Biol 7(3): 182-188. doi:10.1038/nchembio.522. PubMed: 21278739.
29. O'Brate A, Giannakakou P (2003) The importance of p53 location: nuclear or cytoplasmic zip code? Drug Resist Update 6(6): 313-322. doi:10.1016/j.drup. 2003.10.004.
30. Bensaude O (2011) Inhibiting eukaryotic transcription: Which compound to choose? How to evaluate its activity? Transcription. 2(3): 103-108. doi:10.4161/trns.2.3.16172. PubMed: 21922053.
31. Moll UM, Petrenko O (2003) The MDM2-p53 interaction. Mol Cancer Res 1(14): 1001-1008. PubMed: 14707283.
32. Talis AL, Huibregtse JM, Howley PM (1998) The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV)-positive and HPV-negative cells. J Biol Chem 273(11): 6439-6445. doi:10.1074/jbc.273.11.6439. PubMed: 9497376.
33. Dumaz N, Meek DW (1999) Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2. EMBO J 18(24): 7002-7010. doi:10.1093/emboj/18.24.7002. PubMed: 10601022.
34. Kinner A, Wu W, Staudt C, Iliakis G (2008) Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res 36(17): 5678-5694. doi:10.1093/nar/gkn550. PubMed: 18772227.
35. Johnson SM, Wang X, Evers BM (2011) Triptolide inhibits proliferation and migration of colon cancer cells by inhibition of cell cycle regulators and cytokine receptors. J Surg Res 168(2): 197-205. doi:10.1016/j.jss.2009.07.002. PubMed: 19922946.
36. Tan BJ, Tan BH, Chiu GN (2011) Effect of triptolide on focal adhesion kinase and survival in MCF-7 breast cancer cells. Oncol Rep 26(5): 1315-1321. PubMed: 21805042.
37. Wang W, Yang SM, Su Y, Xiao ZY, Wang CY et al. (2007) Enhanced Antitumor Effect of Combined Triptolide andIonizing Radiation. Clin Cancer Res 13: 4891-4899. doi:10.1158/1078-0432.CCR-07-0416. PubMed: 17699869.
38. Tan W, Lu J, Huang M, Li Y, Chen M et al. (2011) Anti-cancer natural products isolated from chinese medicinal herbs. Chin Med. 6(1): 27. doi:10.1186/1749-8546-6-27. PubMed: 21777476.
39. Kim MJ, Lee TH, Kim SH, Choi YJ, Heo J et al. (2010) Triptolide inactivates Akt and induces caspase-dependent death in cervical cancer cells via the mitochondrial pathway. Int J Oncol 37(5): 1177-1185. PubMed: 20878065.
40. Wang W, Lin W, Hong B, Li X, Zhang M et al. (2012) Effect of triptolide on malignant peripheral nerve sheath tumours in vitro and in vivo. J Int Med Res 40(6): 2284-2294. doi:10.1177/030006051204000626. PubMed: 23321185.
41. Lu N, Liu J, Liu J, Zhang C, Jiang F et al. (2012) Antagonist effect of triptolide on AKT activation by truncated retinoid X receptor-alpha. PLOS ONE. 7(4): e35722. doi:10.1371/journal.pone.0035722. PubMed: 22545132.
42. Carter BZ, Mak DH, Schober WD, McQueen T, Harris D et al. (2006) Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood. 108(2): 630-637. doi: 10.1182/blood-2005-09- 3898. PubMed: 16556893.
43. Panichakul T, Intachote P, Wongkajorsilp A, Sripa B, Sirisinha S (2006) Triptolide sensitizes resistant cholangiocarcinoma cells to TRAIL-induced apoptosis. Anticancer Res 26(1A): 259-265. PubMed: 16475706.
44. Wang Y, Lu JJ, He L, Yu Q (2011) Triptolide (TPL) inhibits global transcription by inducing proteasome-dependent degradation of RNA polymerase II (Pol II). PLOS ONE. 6(9): e23993. doi:10.1371/journal.pone.0023993. PubMed: 21931633.
45. Manzo SG, Zhou ZL, Wang YQ, Marinello J, He JX et al. (2012) Natural product triptolide mediates cancer cell death by triggering CDK7-dependent degradation of RNA polymerase II. Cancer Res 72(20): 5363-5373. doi:10.1158/0008-5472.CAN-12-1006. PubMed: 22926559.
46. Jiang XH, Wong BC, Lin MC, Zhu GH, Kung HF et al. (2001) Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells. Oncogene. 20(55): 8009-8018. doi:10.1038/sj.onc.1204981. PubMed: 11753684.
47. Kiviharju TM, Lecane PS, Sellers RG, Peehl DM (2002) Antiproliferative and proapoptotic activities of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells. Clin Cancer Res 8(8): 2666-2674. PubMed: 12171899.
48. Vispé S, DeVries L, Créancier L, Besse J, Bréand S et al. (2009) Triptolide is an inhibitor of RNA polymerase I and II-dependent transcription leading predominantly to down-regulation of short-lived mRNA. Mol Cancer Ther 8(10): 2780-2790. doi:10.1158/1535-7163.MCT-09-0549. PubMed: 19808979.
49. Xiaowen H, Yi S (2012) Triptolide sensitizes TRAIL-induced apoptosis in prostate cancer cells via p53-mediated DR5 up-regulation. Mol Biol Rep 39(9): 8763-8770. doi:10.1007/s11033-012-1737-2. PubMed: 22707197.
50. Matsui Y, Watanabe J, Ikegawa M, Kamoto T, Ogawa O et al. (2008) Cancer-specific enhancement of cisplatin-induced cytotoxicity with triptolide through an interaction of inactivated glycogen synthase kinase-3beta with p53. Oncogene. 27(33): 4603-4614. doi:10.1038/onc.2008.89. PubMed: 18391982.
51. Huang M, Zhang H, Liu T, Tian D, Gu L et al. (2013) Triptolide inhibits MDM2 and induces apoptosis in acute lymphoblastic leukemia cells through a p53-independent pathway. Mol Cancer Ther 12(2): 184-194. doi:10.1158/1535-7163. MCT-12-0425. PubMed: 23243057.
52. Hellin AC, Calmant P, Gielen J, Bours V, Merville MP (1998) Nuclear factor - kappaB-dependent regulation of p53 gene expression induced by daunomycin genotoxic drug. Oncogene. 16(9): 1187-1195. doi:10.1038/sj.onc. 1201638. PubMed: 9528861.
53. Wang S, El-Deiry WS (2006) p73 or p53 directly regulates human p53 transcription to maintain cell cycle checkpoints. Cancer Res 66(14): 6982-6989. doi:10.1158/0008-5472.CAN-06-0511. PubMed: 16849542.
54. Vilborg A, Wilhelm MT, Wiman KG (2010) Regulation of tumor suppressor p53 at the RNA level. J Mol Med (Berl). 88(7): 645-652. doi:10.1007/s00109-010- 0609-2. PubMed: 20306257.
55. Vilborg A, Glahder JA, Wilhelm MT, Bersani C, Corcoran M et al. (2009) The p53 target Wig-1 regulates p53 mRNA stability through an AU-rich element. Proc Natl Acad Sci U S A 106(37): 15756-15761. doi:10.1073/pnas.0900862106. PubMed: 19805223.
56. Takagi M, Absalon MJ, McLure KG, Kastan MB (2005) Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. Cell. 123(1): 49-63. doi:10.1016/j.cell.2005.07.034. PubMed: 16213212.
57. Chen J, Guo K, Kastan MB (2012) Interactions of nucleolin and ribosomal protein L26 (RPL26) in translational control of human p53 mRNA. J Biol Chem 287(20): 16467-16476. doi:10.1074/jbc.M112.349274. PubMed: 22433872.
58. Chueh FS, Chen YL, Hsu SC, Yang JS, Hsueh SC et al. (2013) Triptolide induced DNA damage in A375.S2 human malignant melanoma cells is mediated via reduction of DNA repair genes. Oncol Rep 29(2): 613-618. PubMed: 23233170.
59. Adhim Z, Otsuki N, Kitamoto J, Morishita N, Kawabata M et al. (2013) Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention against head and neck cancer-containing HPV16 cell lines. Acta Otolaryngol, 133: 761-71. PubMed: 23638950.
60. Chaturvedi AK (2012) Epidemiology and clinical aspects of HPV in head and neck cancers. Head Neck Pathol 6(1): S16-S24. doi:10.1007/s12105-011-0304-9. PubMed: 22782220.
61. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C (2006) Clonogenic assay of cells in vitro. Nat Protoc 1(5): 2315-2319. doi:10.1038/nprot.2006. 339. PubMed: 17406473.